Investigational drug · Phase 3
IBI363
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
20
Any phase or sponsor naming "IBI363"
First trial start
2023
Oct 19, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI363", any sponsor or status.
- Phase 214
Conditions studied
As listed on its trial records.
- Melanoma
- Colorectal Cancer
- Resectable Stage II-III Non-small Cell Lung Cancer
- Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
- EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
- Non-small Cell Lung Cancer
- Renal Cell Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Melanoma · Ovarian cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI363" as an intervention, largest first.
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07307053 · 600 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 31, 2029
Drug: BL-B01D1; VSV injection and 18 more · For: Rare Malignant Neoplasm; Advanced Solid Tumors; Metastatic Solid Tumors
- A Study of IBI363 in Subjects With Advanced MalignanciesPivotal-lookingRecruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06468098 · 556 participants (planned) · Start Jun 15, 2024 · Primary completion Jun 30, 2025
Drug: IBI363 + chemotherapy; IBI363 + Investigator's Choice SOC · For: Advanced Malignancies
Sites: Shanghai, China
- IBI363 Combined With Bevacizumab for Advanced Colorectal CancerPivotal-lookingRecruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07722494 · 550 participants (planned) · Start Jul 31, 2026 · Primary completion Oct 31, 2028
Drug: IBI363 + bevacizumab; Investigator's choice of therapy · For: Colorectal Cancer
Sites: Wuhan, China; Hangzhou, China
- Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or LymphomaActive, not recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05460767 · 504 participants · Start Aug 31, 2022 · Primary completion Dec 31, 2026
Drug: IBI363; Bevacizumab · For: Solid Tumors or Lymphoma
Sites: Hangzhou, China
Hunan Province Tumor HospitalAcademic, hospital or other
NCT06081907 · 430 participants (planned) · Start Dec 25, 2023 · Primary completion Dec 1, 2026
Drug: IBI363; IBI363 and 3 more · For: Advanced Solid Tumor
Sites: Changsha, China
- Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialPivotal-lookingNot yet recruiting
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT06620822 · 296 participants (planned) · Start Sep 30, 2024 · Primary completion Sep 30, 2026
Drug: IBI363; LM-108+Sintilimab and 2 more · For: Non Small Cell Lung Cancer
Sites: Shanghai, China
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT06717880 · 260 participants (planned) · Start Jul 28, 2023 · Primary completion Jul 31, 2025
Drug: IBI363 combined with Bevacizumab; IBI363 + Furuitinib · For: Advanced Malignancies
Sites: Wuhan, China
- A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyPivotal-lookingActive, not recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06797297 · 203 participants · Start Feb 24, 2025 · Primary completion Dec 31, 2026
Drug: IBI363; Pembrolizumab · For: Melanoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 31 sites in all
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06081920 · 180 participants (planned) · Start Oct 19, 2023 · Primary completion Oct 19, 2028
Drug: IBI363 · For: Melanoma
Sites: Beijing, China; Fuzhou, China; Zhengzhou, China · 12 sites in all
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06281678 · 178 participants (planned) · Start Apr 8, 2024 · Primary completion Mar 1, 2026
Drug: IBI363 · For: Melanoma; Non-small Cell Lung Cancer; Colorectal Cancer and 1 more
Sites: San Francisco, California; Ocala, Florida; Plantation, Florida · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy.
Xu C, Yan T, Wen S, et al. · BioDrugs 2026
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- CeralasertibAZD6738Phase 35 trials
AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.